Clinical Trails

A phase 2 clinical trial of the experimental drug elraglusib has shown promising results for patients with metastatic pancreatic cancer, according to research published in Nature Medicine. Patients who received elraglusib along with chemotherapy were twice as likely to be alive after one year compared to those who received chemotherapy alone, with survival rates of […]

The combination of darlifarnib with cabozantinib may overcome treatment resistance in advanced clear cell renal cell carcinoma. The study tested a “re-challenge” approach, where darlifarnib helps tumors respond again to cabozantinib, even in patients who had previously progressed on the same drug. This suggests a new way to extend the usefulness of existing therapies. In

Interim results show promising activity for rezatapopt (PC14586) in patients with advanced ovarian cancer carrying the TP53 Y220C mutation. Rezatapopt is a first-in-class oral drug designed to restore the function of the mutated p53 protein, a key tumor suppressor. By stabilizing this specific mutation, the drug helps cancer cells regain normal growth control, offering a

The EZH2 inhibitor mevrometostat is moving into phase 3 trials as a potential treatment for metastatic castration-resistant prostate cancer after encouraging early results. The approach targets EZH2, an epigenetic regulator that helps cancer cells become more aggressive and resistant to treatment, including androgen receptor pathway inhibitors like enzalutamide. In a phase 1 study, combining mevrometostat

A phase 1 trial suggests that the multipeptide T-cell activator iTAC-XS15-CLL could be a safe and promising immunotherapy for patients with chronic lymphocytic leukemia receiving BTK inhibitors. The study enrolled 20 patients with minimal residual disease who were in partial remission after treatment with ibrutinib, acalabrutinib, or zanubrutinib. Each patient received three doses of a

Partner Therapeutics has submitted a supplemental application to the U.S. Food and Drug Administration seeking approval of zenocutuzumab-zbco for adults with advanced or metastatic cholangiocarcinoma carrying NRG1 gene fusions. The National Comprehensive Cancer Network has already added the drug to its guidelines as a recommended option in biliary tract cancers. The submission is supported by

Interim results from the phase 2 ALPHA3 trial suggest that cema-cel, an off-the-shelf CAR T-cell therapy, may significantly improve outcomes for patients with large B-cell lymphoma who remain MRD-positive after initial treatment. In this high-risk group, the therapy achieved MRD negativity in 58.3% of patients, compared to just 16.7% with standard observation. Circulating tumor DNA

A phase 1 trial shows that a dual-target CAR T-cell therapy called AZD0120 is highly effective and safe for older adults with newly diagnosed multiple myeloma, including frail patients. The study included patients with a median age of 72 and found extremely strong early results. All patients achieved a complete response and no detectable cancer

CellCentric has treated the first patient in the DOMMINO-1 trial, a Phase 2 study testing an all-oral combination of inobrodib, pomalidomide, and dexamethasone (InoPd) for patients with heavily pretreated, relapsed or refractory multiple myeloma. The trial plans to enroll 100 patients in the US and UK, focusing on those who are “triple-class refractory” and often

Results from a Phase 1 study show that Erda-iDRS (TAR-210), a new drug-delivery system placed directly into the bladder, appears to be both safe and effective for patients with FGFR-altered non–muscle-invasive bladder cancer. In high-risk patients, the treatment kept cancer from coming back for a median of 20 months, with 83% of patients remaining recurrence-free